Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan

Executive Summary

Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)

You may also be interested in...

Abraxane sNDA Is 505(b)(2) Test, But Panel Has Efficacy, Labeling Questions

One obstacle to using the 505(b)(2) pathway for approving efficacy supplements appears to be how to characterize an agent's effectiveness in labeling

Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight

Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway

Hypertension Class Labeling Does Not Release Sponsors From Large Trials

FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts